Samantha Peng

Since joining Kirkland & Ellis, Samantha has been involved in the following:

• Fangzhou Inc. (HKSE: 6086), the largest online chronic disease management platform in China in terms of average monthly active users in 2023, on the global offering and listing on The Stock Exchange of Hong Kong Limited on July 9, 2024
• The joint sponsors and underwriters on the global offering and listing of Dida Inc. (HKSE: 02559) on The Stock Exchange of Hong Kong Limited on June 28, 2024. China International Capital Corporation Hong Kong Securities Limited, Haitong International Capital Limited and Nomura International (Hong Kong) Limited acted as the joint sponsors for this transaction
• Super Hi International Holding Ltd. (HKSE: 9658; NASDAQ: HDL) on its initial public offering on the Nasdaq Global Market, making it the first high-profile company to list first in Hong Kong and then in the United States in recent years
• Goldman Sachs (Asia) L.L.C., Citigroup Global Markets Limited and J.P. Morgan Securities (Asia Pacific) Limited, in connection with the H-share placing of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. The net proceeds from the H-Share Placing amounted to approximately HK$541.4 million
• The joint sponsors and underwriters on the global offering and listing of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKSE: 1541), a leading science-driven biotechnology company dedicated to the development of immuno-oncology therapies in China, on the Hong Kong Exchanges and Clearing Limited on September 5, 2023
• Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKSE: 6990) on its US$174 million global offering and listing on the The Stock Exchange of Hong Kong Limited on July 11, 2023. This transaction was named “Best IPO - Hong Kong SAR” by FinanceAsia Achievement Awards 2023
• Super Hi International Holdings Ltd. (HKSE: 9658) on its listing by way of introduction on the Main Board of the Stock Exchange of Hong Kong Limited on December 30, 2022, which constituted a spin-off of Super Hi from the hotpot giant Haidilao International Holding Ltd. (HKSE: 6862) and its separate listing on the Stock Exchange. Super Hi is a leading international Chinese restaurant brand. Morgan Stanley Asia Limited and Huatai Financial Holdings (Hong Kong) Limited were the joint sponsors
• Yunkang Group Limited (HKSE: 2325), a leading medical operation service provider in China that offers a full suite of diagnostic testing services for medical institutions, on its approximately US$140 million global offering and listing on The Stock Exchange of Hong Kong Limited 
• Jiangsu Recbio Technology Co., Ltd. (HKSE: 2179), a vaccine company dedicated to the research, development and commercialization of subunit vaccines, on its global offering and listing of H-shares on the Hong Kong Exchanges and Clearing Limited on March 31, 2022 ‒ the first HPV vaccine stock in Hong Kong 
• The joint sponsors and underwriters on the global offering and listing of CANbridge Pharmaceuticals Inc. (HKSE: 1228), a rare disease-focused biopharmaceutical company committed to the research, development and commercialization of biotech therapies, on The Stock Exchange of Hong Kong Limited on December 10, 2021
• Beijing Airdoc Technology Co., Ltd. (HKSE: 2251), a global leader and pioneer in providing AI-empowered retina-based early detection, auxiliary diagnosis and health risk assessment solutions, on its US$215 million global offering and listing on The Stock Exchange of Hong Kong Limited
• Clover Biopharmaceuticals, Ltd. (HKSE: 2197), a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates for infectious disease as well as cancer and autoimmune diseases, on its US$258 million global offering and listing on the The Stock Exchange of Hong Kong Limited 
• Magnum Opus Acquisition Limited (NYSE: OPA), a publicly traded special purpose acquisition company, on its proposed business combination with Forbes Global Media Holdings Inc., the iconic business information brand 
• The joint sponsors and underwriters on the US$400 million global offering and listing of Keymed Biosciences Inc. (HKSE: 2162), a biotechnology company focuses on the in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas, on The Stock Exchange of Hong Kong Limited on July 8, 2021
• Suzhou Basecare Medical Corporate Limited (HKSE: 2170), an innovative platform of genetic testing solutions for assisted reproduction in China, in its $233 million global offering of H-shares and listing on the Hong Kong Exchanges and Clearing Limited
• MicroPort CardioFlow Medtech Corporation (HKSE: 2160) in connection with its US$322 million initial public offering and listing on the Main Board of HKEx. The listing is a spin-off from Hong Kong-listed MicroPort Scientific Corporation. MicroPort CardioFlow is a medical device company in China focusing on the research, development, and commercialization of innovative transcatheter and surgical solutions for valvular heart diseases

Prior to joining Kirkland & Ellis, Samantha has been involved in the following:

• Kangji Medical Holdings Limited (HKSE:9997), in connection with its US$404 million (HK$3.13 billion) initial public offering on the Main Board of the Stock Exchange of Hong Kong. Established in 2004, Kangji Medical is the largest domestic minimally invasive surgical instruments and accessories platform in China
• Alphamab Oncology (HKSE: 9966) in connection with its US$234 million initial public offering listed on the Main Board of The Stock Exchange of Hong Kong. Alphamab Oncology is a leading clinical-stage biopharmaceutical company in China
• CanSino Biologics Inc. (HKSE:6185), in its US$160.5 million global offering and listing of H-Shares on the Main Board of the Stock Exchange of Hong Kong. CanSino Biologics Inc. is a bio-tech leader in research and development, manufacturing and commercialization of vaccine products for human use in China
• Ascletis Pharma Inc. (HKSE:1672) in connection with its US$457 million initial public offering listed on the Main Board of the Stock Exchange of Hong Kong. Ascletis Pharma Inc. is a fully integrated anti-viral platform focusing on developing and commercializing innovative, best-in-class drugs against HCV, HIV and HBV. This is also the first biotech IPO listing under the HKEX’s new listing regime for emerging and innovative sector
• Viva Biotech Holdings (HKSE:1873) in connection with its US$195 million initial public offering listed on the Main Board of the Stock Exchange of Hong Kong Limited. Advised the sole sponsor and underwriters in the offering. Viva Biotech Holdings is a leading open-access and innovation-driven technology platform company
• Yum China Holdings, Inc. (HKSE:9987, NYSE:YUMC) in connection with its secondary listing on the Main Board of The Stock Exchange of Hong Kong. The offering raised net proceeds of approximately HK$17 billion (US$2.2 billion). Yum China is the largest restaurant company in China with flagship brands including KFC and Pizza Hut, as well as emerging brands such as Little Sheep, Huang Ji Huang, COFFii & JOY, East Dawning, Taco Bell, and Lavazza
• Haidilao International Holding Ltd (HKSE: 6862) in connection with its US$964 million initial public offering listed on the Stock Exchange of Hong Kong Main Board. Haidilao International Holding Ltd. is a globally leading and fast-growing Chinese cuisine restaurant brand focusing on hot pot cuisine
• Joy Spreader Interactive Technology. Ltd (HKSE: 6988) in connection with its IPO on the Main Board of HKEx. The offering raised net proceeds of HK$1.56 billion (approximately US$200 million). Joy Spreader is one of the leading performance-based we-media marketing service providers in China
• The joint sponsors and underwriters in connection with the HK$975 million (US$125.74 million) IPO on the Main Board of HKEx of Strawbear Entertainment Group (HKSE: 2125)
• China Bright Culture Group (HKSE: 1859) in connection with its US$116 million initial public offering listed on the Stock Exchange of Hong Kong Main Board. China Bright Culture Group is a rapidly growing independent producer of variety programs in China
• The joint sponsors in connection with CMON Limited (HKSE: 1792)’s transfer of listing from GEM to Mainboard
• China Securities (International) Corporate Finance Company Limited as the sole sponsor and sole global coordinator in connection with Doumob (HKSE: 1917)'s initial public offering listed on the Main Board of the Hong Kong Stock Exchange